Nido Bio is translating today’s neuroscience breakthroughs into tomorrow’s treatments for severe neurological diseases. Leveraging human genetics, we develop precision medicines that address the fundamental biology of disease and restore healthy cell function. NIDO-361, our clinical-stage candidate, is a treatment for Spinal and Bulbar Muscular Atrophy which is a rare and debilitating neuromuscular disease. Additional pipeline programs center around a novel target with the potential to address multiple disease mechanisms and that has broad clinical application across neurodegenerative and peripheral inflammatory diseases. We are creating a sustainable pipeline for the company by utilizing a functional genomics discovery platform based on human cell lines to identify novel targets. Through our approach we seek to transform patient lives in meaningful ways. www.nidobio.com.
Company Details
- Employees
- 11
- Founded
- -
- Address
- The Fundamental Biology Of Disease And Restore Healthy Cell Function. Nido-361
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Nido Biosciences Questions
Nido Biosciences's LinkedIn profile is https://www.linkedin.com/company/nido-biosciences
Nido Biosciences has
11 employees.
View email and phone details for 11
employees at Nido Biosciences.
Nido Biosciences's industry is
Biotechnology Research
Nido Biosciences's top competitors are
Renagade Therapeutics,
Sonothera,
Aera Therapeutics,
Cargo Therapeutics,
Bitterroot Bio,
Abdera Therapeutics,
Apogee Therapeutics,
Orbital Therapeutics,
Rapport Therapeutics,
Belharra Therapeutics.
Nido Biosciences's categories are Biotechnology Research
Nido Biosciences's founding year is 2018
